FR2893848A1 - Phytohormonal composition, useful as hormonal substitute to treat premenopausal, menopausal and androposal disorders, comprises a combination of lignan-rich plant extracts and chaste tree extract - Google Patents
Phytohormonal composition, useful as hormonal substitute to treat premenopausal, menopausal and androposal disorders, comprises a combination of lignan-rich plant extracts and chaste tree extract Download PDFInfo
- Publication number
- FR2893848A1 FR2893848A1 FR0553611A FR0553611A FR2893848A1 FR 2893848 A1 FR2893848 A1 FR 2893848A1 FR 0553611 A FR0553611 A FR 0553611A FR 0553611 A FR0553611 A FR 0553611A FR 2893848 A1 FR2893848 A1 FR 2893848A1
- Authority
- FR
- France
- Prior art keywords
- vitamin
- extract
- weight
- phytohormonal
- standardized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 235000001667 Vitex agnus castus Nutrition 0.000 title claims abstract description 13
- 229930013686 lignan Natural products 0.000 title claims abstract description 11
- 235000009408 lignans Nutrition 0.000 title claims abstract description 11
- 150000005692 lignans Chemical class 0.000 title claims abstract description 11
- 239000000419 plant extract Substances 0.000 title claims abstract description 6
- 239000000284 extract Substances 0.000 title claims description 16
- 230000003054 hormonal effect Effects 0.000 title claims description 4
- 241000532412 Vitex Species 0.000 title 1
- 244000063464 Vitex agnus-castus Species 0.000 claims abstract description 12
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 20
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 18
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 16
- QRYRORQUOLYVBU-VBKZILBWSA-N carnosic acid Chemical compound CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 14
- HKMZDYJMJDPXRP-UHFFFAOYSA-N vitexicarpin Natural products OC1=C2C(C(=C(OC2=CC(=C1OC)OC)C1=CC(=CC(=C1)OC)O)OC)=O HKMZDYJMJDPXRP-UHFFFAOYSA-N 0.000 claims description 14
- PJQLSMYMOKWUJG-UHFFFAOYSA-N casticin Chemical compound C1=C(O)C(OC)=CC=C1C1=C(OC)C(=O)C2=C(O)C(OC)=C(OC)C=C2O1 PJQLSMYMOKWUJG-UHFFFAOYSA-N 0.000 claims description 12
- CCWSQXBMKLEALQ-WMZOPIPTSA-N centaureidin Natural products CO[C@@H]1[C@@H](Oc2cc(O)c(OC)c(O)c2C1=O)c3ccc(OC)c(O)c3 CCWSQXBMKLEALQ-WMZOPIPTSA-N 0.000 claims description 12
- DTPRTOXMYKYSIJ-UHFFFAOYSA-N eupatorin Natural products C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=CC(OC)=C(OC)C=C2O1 DTPRTOXMYKYSIJ-UHFFFAOYSA-N 0.000 claims description 12
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 10
- 235000019158 vitamin B6 Nutrition 0.000 claims description 10
- 239000011726 vitamin B6 Substances 0.000 claims description 10
- 229940011671 vitamin b6 Drugs 0.000 claims description 10
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 9
- 229930003268 Vitamin C Natural products 0.000 claims description 9
- 229940112950 sage extract Drugs 0.000 claims description 9
- 235000020752 sage extract Nutrition 0.000 claims description 9
- 235000019154 vitamin C Nutrition 0.000 claims description 9
- 239000011718 vitamin C Substances 0.000 claims description 9
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 8
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 8
- 229930003427 Vitamin E Natural products 0.000 claims description 8
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 8
- 235000019155 vitamin A Nutrition 0.000 claims description 8
- 239000011719 vitamin A Substances 0.000 claims description 8
- 235000019165 vitamin E Nutrition 0.000 claims description 8
- 239000011709 vitamin E Substances 0.000 claims description 8
- 229940045997 vitamin a Drugs 0.000 claims description 8
- 239000000395 magnesium oxide Substances 0.000 claims description 7
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 7
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 7
- 229940046009 vitamin E Drugs 0.000 claims description 7
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 6
- 235000008696 isoflavones Nutrition 0.000 claims description 6
- AJNRZGCOXRHMEZ-UHFFFAOYSA-N Agnuside Natural products OCC1OC(OC2OC=CC3CC=C(COC(=O)c4ccc(O)cc4)C23)C(O)C(O)C1O AJNRZGCOXRHMEZ-UHFFFAOYSA-N 0.000 claims description 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 5
- GLACGTLACKLUJX-QNAXTHAFSA-N agnuside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@@H]2C(COC(=O)C=3C=CC(O)=CC=3)=C[C@@H](O)[C@@H]2C=CO1 GLACGTLACKLUJX-QNAXTHAFSA-N 0.000 claims description 5
- 229940106574 chaste berry extract Drugs 0.000 claims description 5
- 235000020223 chasteberry extract Nutrition 0.000 claims description 5
- 150000002515 isoflavone derivatives Chemical class 0.000 claims description 5
- 239000011669 selenium Substances 0.000 claims description 5
- 229910052711 selenium Inorganic materials 0.000 claims description 5
- 235000011649 selenium Nutrition 0.000 claims description 5
- 229940091258 selenium supplement Drugs 0.000 claims description 5
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 claims description 4
- 230000009245 menopause Effects 0.000 claims description 4
- 229960000342 retinol acetate Drugs 0.000 claims description 4
- 235000019173 retinyl acetate Nutrition 0.000 claims description 4
- 239000011770 retinyl acetate Substances 0.000 claims description 4
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 claims description 4
- 229960001471 sodium selenite Drugs 0.000 claims description 4
- 239000011781 sodium selenite Substances 0.000 claims description 4
- 235000015921 sodium selenite Nutrition 0.000 claims description 4
- 235000020712 soy bean extract Nutrition 0.000 claims description 4
- 159000000003 magnesium salts Chemical class 0.000 claims description 2
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims 1
- 244000042664 Matricaria chamomilla Species 0.000 claims 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims 1
- 235000011925 Passiflora alata Nutrition 0.000 claims 1
- 235000000370 Passiflora edulis Nutrition 0.000 claims 1
- 235000011922 Passiflora incarnata Nutrition 0.000 claims 1
- 240000002690 Passiflora mixta Species 0.000 claims 1
- 235000013750 Passiflora mixta Nutrition 0.000 claims 1
- 235000013731 Passiflora van volxemii Nutrition 0.000 claims 1
- 244000126014 Valeriana officinalis Species 0.000 claims 1
- 235000013832 Valeriana officinalis Nutrition 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000003712 anti-aging effect Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 229940107657 flaxseed extract Drugs 0.000 claims 1
- 235000020704 flaxseed extract Nutrition 0.000 claims 1
- 235000016788 valerian Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 5
- 239000009186 Vitex agnus castus extract Substances 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 229930003935 flavonoid Natural products 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 235000009347 chasteberry Nutrition 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 208000017657 Menopausal disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- HXDOZKJGKXYMEW-UHFFFAOYSA-N 4-ethylphenol Chemical compound CCC1=CC=C(O)C=C1 HXDOZKJGKXYMEW-UHFFFAOYSA-N 0.000 description 2
- CCOJFDRSZSSKOG-UHFFFAOYSA-N Angolensin Chemical compound C1=CC(OC)=CC=C1C(C)C(=O)C1=CC=C(O)C=C1O CCOJFDRSZSSKOG-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 229940011871 estrogen Drugs 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- CCOJFDRSZSSKOG-SNVBAGLBSA-N Angolensin Natural products C1=CC(OC)=CC=C1[C@@H](C)C(=O)C1=CC=C(O)C=C1O CCOJFDRSZSSKOG-SNVBAGLBSA-N 0.000 description 1
- JHYXBPPMXZIHKG-CYBMUJFWSA-N Dihydrodaidzein Natural products C1=CC(O)=CC=C1[C@@H]1C(=O)C2=CC=C(O)C=C2OC1 JHYXBPPMXZIHKG-CYBMUJFWSA-N 0.000 description 1
- DWONJCNDULPHLV-HOTGVXAUSA-N Enterodiol Chemical compound C([C@@H](CO)[C@H](CO)CC=1C=C(O)C=CC=1)C1=CC=CC(O)=C1 DWONJCNDULPHLV-HOTGVXAUSA-N 0.000 description 1
- AOJXPBNHAJMETF-UHFFFAOYSA-N Enterodiol Natural products OCC(Cc1ccc(O)cc1)C(CO)Cc2ccc(O)cc2 AOJXPBNHAJMETF-UHFFFAOYSA-N 0.000 description 1
- HVDGDHBAMCBBLR-UHFFFAOYSA-N Enterolactone Natural products OC1=CC=CC(CC2C(C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-UHFFFAOYSA-N 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010036618 Premenstrual syndrome Diseases 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 125000003118 aryl group Chemical class 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- JHYXBPPMXZIHKG-UHFFFAOYSA-N dihydrodaidzein Chemical compound C1=CC(O)=CC=C1C1C(=O)C2=CC=C(O)C=C2OC1 JHYXBPPMXZIHKG-UHFFFAOYSA-N 0.000 description 1
- UQGVUYNHDKMLSE-UHFFFAOYSA-N dihydrogenistein Chemical compound C1=CC(O)=CC=C1C1C(=O)C2=C(O)C=C(O)C=C2OC1 UQGVUYNHDKMLSE-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- HVDGDHBAMCBBLR-WMLDXEAASA-N enterolactone Chemical compound OC1=CC=CC(C[C@@H]2[C@H](C(=O)OC2)CC=2C=C(O)C=CC=2)=C1 HVDGDHBAMCBBLR-WMLDXEAASA-N 0.000 description 1
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 description 1
- 235000019126 equol Nutrition 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000006539 genistein Nutrition 0.000 description 1
- TZBJGXHYKVUXJN-UHFFFAOYSA-N genistein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC(O)=C2C1=O TZBJGXHYKVUXJN-UHFFFAOYSA-N 0.000 description 1
- 229940045109 genistein Drugs 0.000 description 1
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 description 1
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 229940056692 resinol Drugs 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/55—Linaceae (Flax family), e.g. Linum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/85—Verbenaceae (Verbena family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
L'invention concerne une composition phytohormonale et son utilisationThe invention relates to a phytohormonal composition and its use
comme substitutif hormonal, comprenant une combinaison d'extraits de végétaux riches en lignanes ou en isoflavones et d'extrait de gattilier, et son utilisation pour le traitement des troubles de la préménopause et de la ménopause, ainsi que de l'andropause. Les troubles de la préménopause et de la ménopause, notamment bouffées de chaleur, sueurs nocturnes, fatigabilité, troubles de l'humeur et du sommeil, sont généralement traités par administration d'un substitut hormonal associant des estrogènes et des progestatifs mais l'administration de telles hormones peut entraîner des effets secondaires indésirables. Par ailleurs, l'andropause s'accompagne de certaines manifestations gênantes comme une augmentation de volume de la prostate entraînant des difficultés mictionnelles, une alopécie andogénique ou encore des problèmes d'érection. Il serait souhaitable de disposer d'un substitut hormonal présentant des effets secondaires moindres et de préférence très limités et ayant une efficacité réelle sur les troubles de la préménopause, de la ménopause et de l'andropause. as a hormonal substitute, comprising a combination of plant extracts rich in lignans or isoflavones and chaste tree extract, and its use for the treatment of menopausal and menopausal disorders, as well as andropause. Premenopausal and menopausal disorders, including hot flushes, night sweats, fatigability, mood and sleep disorders, are generally treated by administering a hormone substitute combining estrogens and progestins, but the administration of such hormones can cause unwanted side effects. In addition, andropause is accompanied by some annoying manifestations such as an increase in the volume of the prostate causing difficulty micturition, alopecia andogenic or erection problems. It would be desirable to have a hormone substitute with lesser and preferably very limited side effects and with real efficacy on premenopausal, menopausal and andropause disorders.
Ceci est obtenu de façon surprenante par l'association d'extraits végétaux donnant une composition phytohormonale permettant de réaliser un traitement substitutif complet de la préménopause, de la ménopause et de l'andropause. L'invention fournit donc une composition phytohormonale comprenant une combinaison d'extraits de végétaux riches en lignanes ou en isoflavones et d'extrait de gattilier (Vitex agnus castus). De manière préférée, cette composition phytohormonale contient en outre un sel de magnésium et de la vitamine B6. De préférence encore, cette composition phytohormonale 30 colide 35 Les lignanes dont les métabolites enterolignanes) sont les phyto-est e -s pt ù t .. c trou-ver sous , lire ou pilée. Ils sont présents dans c s non fruits et l café. C rt 1 fines, en lier la grain la source Tans 1( qui en con , T 4.0 star,"•.r,l i r1111AF L ri rr9I . L , , , . , , 3 6,11 ma11519 (411%,,,, T.&%.,11 -• '= t du métabolisme des l'effet de la flore intestinale de l'organisme. Les entérolignanes peuvent exister sous forme d'oligoméres et de dimères, en tant qu'aglycones ou hétérosides. Les lignanes les plus connus sont le séco-isolaricï-résinol et le matairésinol. Ils sont métabolisés par la flore intestinale en entérodiol et entérolactone qui eux seuls répondent à la définition des phytoestrogénes. Ainsi, les essais portant sur l'activité estrogénique sont-ils faits ar- ès métabolisation des lignanes. Les formules développées de ces cornpc ont données ci s. 20 15 25 30 fruits secs qui en contiennent, en particulier la graine de soja qui est la source la plus employée. Leurs structures sont proches de celle de l'estradiol, un système plan qui inclut un noyau aromatiuqe substitué en para. Les isoflavones peuvent exister sous forme d'aglycones, mais le plus souvent dans les plantes elles se présentent à l'état de glycosides. Dans le tractus gastro-intestinal, la daidzéine est métabolisée en dihydrodaidzéine puis en équol, métabolite hautement estrogénique et la génistéine est métabolisée en dihydrogénistéine, puis en 6'-hydro 0-déméthyl Io angolensine, pour donner le p-éthyl phénol et le tri hydroxy-benzène. Le gattilier (Vitex agnus castus) est un arbuste originaire de Grèce et d'Italie, répandu dans les régions méditerranéennes. Les extraits sont obtenus à partir des baies séchées et contiennent deux flavonoides spécifiques à cette plante, la casticine et l'agnuside. On trouve dans le 15 commerce des extraits standardisés soit en casticine (rapport pondéral de l'extrait à la casticine de 6 à 12 :1) soit en agnuside (de 0,5 % à 6 % en poids d'agnuside dans l'extrait sec), qui se présentent sous forme de teintures, d'extraits liquides ou d'extraits secs. On connaît l'utilisation d'extrait de gattilier pour traiter 20 certains syndromes prémenstruels mais il n'a jusqu'à présent pas été préconisé pour traiter les troubles de la préménopause, de la ménopause et de l'andropause. On a maintenant trouvé de manière surprenante que l'association lignanes ou isoflavones/flavonoïdes du gattilier fournit un 25 subtitut phytohormonal complet traitant de manière efficace et sûre les troubles de la préménopause et de la ménopause. On a également trouvé de manière surprenante que l'association lignanes et flavonoïdes du gattilier pouvait constituer un substitut hormonal pour améliorer certaines manifestations de 30 l'a ,)IIO( tni toii-a- (,fai-i a.1-1 n.r% This is surprisingly obtained by the combination of plant extracts giving a phytohormonal composition for performing a complete replacement treatment for premenopause, menopause and andropause. The invention thus provides a phytohormonal composition comprising a combination of plant extracts rich in lignans or isoflavones and chaste tree extract (Vitex agnus castus). Preferably, this phytohormonal composition further contains a magnesium salt and vitamin B6. More preferably, this phytohormonal 30 colide composition (lignans whose enterolignan metabolites) are phyto-is e -s pt-t .. c hole-ver under, read or crushed. They are present in these fruits and coffee. C tt 1 fines, bind the grain to the source Tans 1 (which in con t? The metabolism of the intestinal flora effect of the organism, enterolignans can exist in the form of oligomers and dimers, as aglycones or glycosides. The most well-known lignans are seco-isolarinic-resinol and matairésinol, which are metabolized by the intestinal flora to enterodiol and enterolactone, which alone meet the definition of phytoestrogens, so that the tests on estrogen activity are The developed formulas of these cornpcs have given dry fruits which contain them, in particular the soybean which is the most widely used source. estradiol, a flat system that includes a para-substituted aromatic ring. They may exist as aglycones, but most often in plants they occur as glycosides. In the gastrointestinal tract, daidzein is metabolized to dihydrodaidzein and then to equol, a highly estrogenic metabolite, and genistein is metabolized to dihydrogenistein and then to 6'-hydro-0-demethyl Io angolensin to give p-ethyl phenol and sorting. hydroxy benzene. Chaste tree (Vitex agnus castus) is a shrub native to Greece and Italy, widespread in the Mediterranean regions. The extracts are obtained from dried berries and contain two flavonoids specific to this plant, casticine and agnuside. Standardized extracts are commercially available either in casticin (weight ratio of the extract to casticin of 6 to 12: 1) or in agnuside (from 0.5% to 6% by weight of agnuside in the extract). dry), which are in the form of dyes, liquid extracts or dry extracts. The use of Chasteberry extract is known to treat some premenstrual syndromes but has not heretofore been advocated for the treatment of premenopausal, menopausal and andropause disorders. It has now surprisingly been found that the lignans or isoflavones / flavonoids combination of chaste tree provides a complete phytohormonal subtitut which effectively and safely addresses premenopausal and menopausal disorders. It has also surprisingly been found that the combination of lignans and flavonoids in the chaste tree can be a hormone substitute for improving certain manifestations of the disease. %
4 de 10 mg à 40 mg d'extrait de gattilier standardisé à 0,5 % - 6 % en poids d'agnuside ou standardisé à 6-12:1 de casticine (rapport pondéral extrait : casticine), de 25 mg à 100 mg d'extrait de sauge standardisé à 15 % en poids d'acide carnosique, de 100 . 300 mg d'Vi-sv-crelACUL, z, magnésium mg 111 • de 2 mg à 4 mg de vitamine B6, • de 50 mg à 100 mg de vitamine C, de 5 mg à 15 mg de sélénium, de 1 mg à 2 mg de vitamine A, de 5 mg à 15 mg de vitamine E. Elle fournit également une composition phytohormonale contenant en poids sec de 50 mg à 200 mg d'extrait de graines de soja contenant de 10 à 30 % en poids d'isoflanones, de 10 mg à 40 mg d'extrait de gattilier standardisé à 0,5 % - 6 % en poids d'agnusides ou standardisé à 6-12:1 de casticine (rapport pondéral extrait :casticine) de 25 mg à 100 mg d'extrait de sauge standardié à 15 % en poids d'acide carnosique, • de 100 mg à 300 mg d'oxyde de magnésium, • de 2 mg à 4 mg de vitamine B6, • de 50 mg à 100 mg de vitamine C, • de 5 mg à 15 mg de sélénium, • de 1 mg à 2 mg de vitamine A, • de 5 mg à 15 mg de vitamine E. De telles compositions sont, selon l'invention, utilisées comme substitutif hormonal dans le traitement des troubles de la préménopause, d- la ménopause et p opause. 35 être présentés séparément, en combinaison de deux ou plusieurs éléments ou dans une seule préparation posologique. 1. Exemple de composition lignagnes/flavonoïdes de gattilier (en poids sec) pour une dose quotidienne 5 105 mg d'extrait de graines de lin à 20 % en poids de lignanes exprimés en SDG (SecoisolarieirésinolDiGlucoside), 20 mg d'extrait de gattilier à 0,6 % de casticine, 50 mg d'extrait de sauge standardisé à 15 % en acide carnosique, 290 mg d'oxyde de magnésium, 3,18 mg de vitamine B6 à 82 % de produit actif, 87,00 mg de vitamine C à 90 % de produit actif, 10 mg de sélénite de sodium, 12 mg d'acétate de rétinol à 10 % de vitamine A, 32,00 mg de préparation de vitamine E contenant 37,00 % de produit actif, 2. Exemple de composition isoflavones/flavonoïdes de gattilier (en poids sec) pour une dose quotidienne 100 mg d'extrait de graines de soja à 20 % en poids d'isoflavo~ es, 20 mg d'extrait de gattilier à 0,6 % de casticine, 50 mg d'extrait de sauge standardisé à 15 % en acide carnosique, 290 mg d'oxyde de magnésium, 3,18 mg de vitamine B6 à 82 % de produit actif, 87,00 mg de vitamine C à 90 % de produit actif, 10 mg de sélénite de sodium, 12 mg d'acétate de rétinol à 10 % de vitamine A, 32,00 mg de préparation de vitamine E contenant 37,00 % de produit actif, 4 from 10 mg to 40 mg standardized 0.5% - 6% by weight agnuside or standardized 6-12: 1 casticin extract extract (extracted weight ratio: casticin), from 25 mg to 100 mg of sage extract standardized to 15% by weight of carnosic acid, of 100. 300 mg Vi-sv-crelACUL, z magnesium mg 111 • 2 mg to 4 mg vitamin B6, • 50 mg to 100 mg vitamin C, 5 mg to 15 mg selenium, 1 mg to 2 mg of vitamin A, from 5 mg to 15 mg of vitamin E. It also provides a phytohormonal composition containing in dry weight from 50 mg to 200 mg of soybean extract containing from 10 to 30% by weight of isoflanones , from 10 mg to 40 mg of chasteberry extract standardized to 0.5% - 6% by weight of agnusides or standardized to 6-12: 1 of casticin (extracted weight ratio: casticin) of 25 mg to 100 mg of sage extract standardized to 15% by weight of carnosic acid, • from 100 mg to 300 mg of magnesium oxide, • from 2 mg to 4 mg of vitamin B6, • from 50 mg to 100 mg of vitamin C, From 5 mg to 15 mg of selenium, from 1 mg to 2 mg of vitamin A, from 5 mg to 15 mg of vitamin E. Such compositions are, according to the invention, used as a hormonal substitute in the treatment of disorders of the meadow menopause, d- menopause and p opause. Be presented separately, in combination of two or more elements or in a single dosage preparation. 1. Example of lignain / flavonoid composition of Chasteberry (dry weight) for a daily dose 105 mg of linseed extract containing 20% by weight of lignans expressed in SDG (secoisolarieirésinolDiGlucoside), 20 mg of chaste tree extract 0.6% casticin, 50 mg standardized sage extract 15% carnosic acid, 290 mg magnesium oxide, 3.18 mg vitamin B6 82% active, 87.00 mg of vitamin C 90% active, 10 mg sodium selenite, 12 mg retinol acetate 10% vitamin A, 32.00 mg vitamin E preparation containing 37.00% active product, 2. Example of isoflavone / flavonoid composition of Chasteberry (dry weight) for a daily dose 100 mg of soybean extract with 20% by weight of isoflavo ~ es, 20 mg of chaste extract with 0.6% of casticin, 50 mg of standardized sage extract with 15% carnosic acid, 290 mg of magnesium oxide, 3.18 mg of vitamin B6 with 82% of active product, 8 7.00 mg vitamin C 90% active, 10 mg sodium selenite, 12 mg retinol acetate 10% vitamin A, 32.00 mg vitamin E preparation containing 37.00% of active product,
Claims (4)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0553611A FR2893848B1 (en) | 2005-11-28 | 2005-11-28 | PHYTOHORMONAL COMPOSITION AND ITS USE AS A HORMONAL SUBSTITUTE |
| PCT/FR2006/051220 WO2007060368A1 (en) | 2005-11-28 | 2006-11-23 | Phytohormonal composition and use thereof as hormonal substitute |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0553611A FR2893848B1 (en) | 2005-11-28 | 2005-11-28 | PHYTOHORMONAL COMPOSITION AND ITS USE AS A HORMONAL SUBSTITUTE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2893848A1 true FR2893848A1 (en) | 2007-06-01 |
| FR2893848B1 FR2893848B1 (en) | 2011-11-11 |
Family
ID=37067449
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR0553611A Expired - Fee Related FR2893848B1 (en) | 2005-11-28 | 2005-11-28 | PHYTOHORMONAL COMPOSITION AND ITS USE AS A HORMONAL SUBSTITUTE |
Country Status (2)
| Country | Link |
|---|---|
| FR (1) | FR2893848B1 (en) |
| WO (1) | WO2007060368A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2940123A1 (en) * | 2008-12-22 | 2010-06-25 | Granions Lab Des | Combination product, useful e.g. to treat hot flushes and sweats caused by menopause, comprises compound having direct estrogenic activity at the level of estrogen receptors and compound able to be converted into enterolactone in body |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020122834A1 (en) * | 2000-12-22 | 2002-09-05 | Trant Aileen Sontag | Method and composition for improving fertility health in female and male animals and humans |
| WO2002074321A1 (en) * | 2001-03-21 | 2002-09-26 | N.V. Nutricia | Composition comprising cocoa and a dopamine d2 receptor agonist |
| DE10127897A1 (en) * | 2001-06-08 | 2002-12-19 | Bionorica Ag | Combined pharmaceutical formulation for treating osteoporosis or related disorders, comprising core of dried plant extract enclosed in sheath of calcium salt |
| GB2377439A (en) * | 2001-05-09 | 2003-01-15 | Novartis Nutrition Ag | Ethanol extraction of Vitex agnus castus |
| WO2003086080A1 (en) * | 2002-04-08 | 2003-10-23 | The Daily Wellnes Company | Method and composition for improving fertility health in female and male animals and humans |
| EP1502597A1 (en) * | 2003-07-25 | 2005-02-02 | MARFARMA HOLDING S.p.A. | Compositions for the treatment of anxiety and associated disorders |
| US20050129783A1 (en) * | 2001-04-19 | 2005-06-16 | Mccleary Edward L. | Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10204637A1 (en) * | 2001-02-05 | 2002-11-07 | Greither Salus Haus Dr Otto | Pharmaceutical, nutritional or food additive composition containing gamma-linolenic acid, isoflavone and lignan, is effective e.g. against tumors, osteoporosis and premenstrual syndrome |
-
2005
- 2005-11-28 FR FR0553611A patent/FR2893848B1/en not_active Expired - Fee Related
-
2006
- 2006-11-23 WO PCT/FR2006/051220 patent/WO2007060368A1/en active Application Filing
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020122834A1 (en) * | 2000-12-22 | 2002-09-05 | Trant Aileen Sontag | Method and composition for improving fertility health in female and male animals and humans |
| WO2002074321A1 (en) * | 2001-03-21 | 2002-09-26 | N.V. Nutricia | Composition comprising cocoa and a dopamine d2 receptor agonist |
| US20050129783A1 (en) * | 2001-04-19 | 2005-06-16 | Mccleary Edward L. | Composition and method for treatment of neurophysiological conditions and maintenance of neurophysiological health |
| GB2377439A (en) * | 2001-05-09 | 2003-01-15 | Novartis Nutrition Ag | Ethanol extraction of Vitex agnus castus |
| DE10127897A1 (en) * | 2001-06-08 | 2002-12-19 | Bionorica Ag | Combined pharmaceutical formulation for treating osteoporosis or related disorders, comprising core of dried plant extract enclosed in sheath of calcium salt |
| WO2003086080A1 (en) * | 2002-04-08 | 2003-10-23 | The Daily Wellnes Company | Method and composition for improving fertility health in female and male animals and humans |
| EP1502597A1 (en) * | 2003-07-25 | 2005-02-02 | MARFARMA HOLDING S.p.A. | Compositions for the treatment of anxiety and associated disorders |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2940123A1 (en) * | 2008-12-22 | 2010-06-25 | Granions Lab Des | Combination product, useful e.g. to treat hot flushes and sweats caused by menopause, comprises compound having direct estrogenic activity at the level of estrogen receptors and compound able to be converted into enterolactone in body |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2007060368A1 (en) | 2007-05-31 |
| FR2893848B1 (en) | 2011-11-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Vacca et al. | Plant polyphenols as natural drugs for the management of Down syndrome and related disorders | |
| Mäkynen et al. | Cultivar variations in antioxidant and antihyperlipidemic properties of pomelo pulp (Citrus grandis [L.] Osbeck) in Thailand | |
| Hunt et al. | Effect of St. John's wort on free radical production | |
| Suryakumar et al. | Medicinal and therapeutic potential of Sea buckthorn (Hippophae rhamnoides L.) | |
| US20120135094A1 (en) | Oregano and mint anti-inflammatory compositions and methods | |
| CN117224593A (en) | Compositions and methods for managing or improving bone disorders, cartilage disorders, or both | |
| JP2019523307A (en) | Method for preparing active extract and its application | |
| CA3002753A1 (en) | Specific nutritional or therapeutic agent including a mixture of grape and blueberry | |
| Sani et al. | Effects of three medicinal plants extracts in experimental diabetes: Antioxidant enzymes activities and plasma lipids profiles incomparison with metformin | |
| Magni et al. | Flavonoids bridging the gut and the brain: Intestinal metabolic fate, and direct or indirect effects of natural supporters against neuroinflammation and neurodegeneration | |
| FR3072874A1 (en) | PARTICULAR EXTRACT OF PERFUMES, AROMATIC AND MEDICINAL PLANTS, PROCESS FOR OBTAINING THEM, COMPOSITIONS INCLUDING THE SAME AND USES THEREOF | |
| Cock et al. | Bioactive compounds sourced from Terminalia spp. in bacterial malodour prevention: An effective alternative to chemical additives | |
| Veskoukis et al. | Grape stem extracts from three native Greek vine varieties exhibit strong antioxidant and antimutagenic properties | |
| Asiwe et al. | Up-regulation of B-cell lymphoma factor-2 expression, inhibition of oxidative stress and down-regulation of pro-inflammatory cytokines are involved in the protective effect of cabbage (Brassica oleracea) juice in lead-induced endothelial dysfunction in rats | |
| TW201733619A (en) | Composition for inhibiting carnosine dipeptidase | |
| Morissette et al. | Natural phytoestrogens: A class of promising neuroprotective agents for Parkinson disease | |
| Tauchen et al. | Garcinia kola: a critical review on chemistry and pharmacology of an important West African medicinal plant | |
| FR2908604A1 (en) | Food supplement useful to prevent or fight against androgenic alopecia, hair loss, the hyperseborrhea, acne and hirsutism, comprises green tea extract, another plant extract comprising quercetin and zinc | |
| Su et al. | Polyphenols as potential preventers of osteoporosis: A comprehensive review on antioxidant and anti-inflammatory effects, molecular mechanisms, and signal pathways in bone metabolism | |
| Rajput et al. | Role of polyphenolic compounds and their nanoformulations: A comprehensive review on cross-talk between chronic kidney and cardiovascular diseases | |
| FR2893848A1 (en) | Phytohormonal composition, useful as hormonal substitute to treat premenopausal, menopausal and androposal disorders, comprises a combination of lignan-rich plant extracts and chaste tree extract | |
| Orodan et al. | Phytochemical analysis, antimicrobial and antioxidant effect of some gemmotherapic remedies used in respiratory diseases | |
| Sharma et al. | Flavonoid composition and antioxidant efficacy of citrus peels: an integrated in vitro and in silico approach toward potential neuroprotective agents | |
| Mishra et al. | Therapeutic and Pharmacological Potential of Prunus domestica: A Comprehensive Review | |
| FR2898059A1 (en) | Phytohormonal composition useful to prevent and fight against (pre)menopausal disorders e.g. hot flashes, night sweats, fatigability and mood and sleep disorders, comprises combination of herbal extracts rich in lignans and sage extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| TP | Transmission of property | ||
| CD | Change of name or company name |
Owner name: LABORATOIRES NUTREOV, FR Effective date: 20120323 |
|
| TP | Transmission of property |
Owner name: LABORATOIRES NUTREOV, FR Effective date: 20120323 |
|
| PLFP | Fee payment |
Year of fee payment: 11 |
|
| PLFP | Fee payment |
Year of fee payment: 12 |
|
| PLFP | Fee payment |
Year of fee payment: 13 |
|
| PLFP | Fee payment |
Year of fee payment: 14 |
|
| ST | Notification of lapse |
Effective date: 20200910 |